October 2010

Contents

Conference reports

• 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 12–-15 September 2010, Boston

• Raltegravir pharmacokinetics inpregnancy

• Low birth weight associated with HAART in pregnancy in Zambia

• Bilirubin levels in infants following in utero atazanavir exposure compared to exposure to other antiretrovirals

• Novel mutations and shifting susceptibility to darunavir and tipranavir

• Four-drug single-pill antiretroviral equivalent to Atripla at 48 weeks

• High rates of bone loss and progression with HIV in longitudinal study

• XVIII International AIDS Conference: 18–-23 July 2010, Vienna

• Spray-dried nanoparticle formulation of efavirenz

• Switching boosted-PIs to raltegravir

• Scaling up: what to do first?

• A new point of care CD4 test

• Early infant diagnosis

• Efavirenz-based regimens among womenof reproductive age receiving ART in Johannesburg

• Male circumcision retains effectiveness at reducing risk of HIV infection: 54 month results

• Towards a cure: HIV reservoirs and strategies to control them, 16-–17 July 2010, Vienna

• Rapporteur summaries

Antiretrovirals

• START study given green light for full study

• Saquinavir prolongation of QT interval: Rocheissue Dear Doctor letter

• Development of chronic kidney disease and antiretroviral use in EuroSIDA cohortsince 2004

Treatment access

• FDA approval of generic ARVs

• IAS highlight funding shortfall crisis for Global Fund

• The need for expanded access to experimental medicines for drug-resistant TB

• Indian activists challenge proposed EU tradeagreements: Global access to Indian generic ARVs threatened

• Russian HIV activists arrested in Red Square for protesting drug stock-outs

• Chinese HIV positive activist Tian Xi to go on trial on trumped up charges

• US waiting lists increase by over 300% in five months

Women's health

• HPV-based screen-and-treat is effective for cervical cancer prevention in HIV-positive women

• Genital tract viral load in women with below detectable plasma viral load

Pregnancy

• Test and treat for all pregnant women in low and middle income countries?

• Retrospective analysis finds higher prevalence of birth defects associated with efavirenz than previously reported

Paediatric care

• US paediatric guidelines updated (August 2010)

• Daily cotrimoxazole preferable to intermittent preventative therapy inHIV-infected children

Guidelines

• BHIVA monitoring guidelines online for comment (2010)

Side effects

• Tesamorelin for reduction of central fat accumulation: regulatory decision delayed in the US

Basic science and immunology

• Signs of progress in gene therapy for HIV

PDFs

• Volume 11Number 9/10 September/October 2010 PDF